No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
Eli Lilly's Options: A Look at What the Big Money Is Thinking
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,146